Plasma IGF-1 Could Be Important Parkinson Disease Biomarker – AJMC.com Managed Markets Network

Levels of the hormone increase with disease severity, a new study has found.
Plasma levels of insulin-like growth factor 1 (IGF-1) could give clinicians a better understanding of whether a patient with Parkinson disease (PD) is likely experiencing nonmotor symptoms of the disease, including anxiety, depression, and cognitive decline, a new report has found.

The study, published in Neuroscience Letters, also shows that plasma IGF-1 was associated with the volumes of 3 areas of the brain: the insula, caudate, and anterior cingulate.

There currently are no reliable biomarkers to diagnose preclinical PD, explained the authors. However, they added that IGF-1 is seen as a promising potential biomarker, since the 70–amino acid peptide hormone plays important roles in neuroplasticity, differentiation, myelination, and survival.

“Studies have shown that IGF-1 possesses neuroprotective effects against dopamine-induced toxicity and may have a potential role in the treatment of PD,” they wrote. “Therefore, we hypothesized that plasma IGF-1 levels would be gradually increased as PD progressed.”

The investigators recruited 55 healthy controls and 119 patients with PD. Of the latter group, 67 were in early stages of the disease and the remaining 52 were in middle-late stages. Enrollees had plasma IGF-1 levels assessed by an automatic chemical analyzer, and the patients with PD were assessed for motor and nonmotor symptoms using common disease scales. In addition, 65 patients underwent MRI and voxel-based morphometry to evaluate gray matter changes.

As the authors had hypothesized, the study found that levels of plasma IGF-1 appeared to increase as a patient’s PD case worsened.

“Plasma IGF-1 levels in early-stage PD patients were higher than those in healthy controls, and plasma IGF-1 levels in middle- to late-stage PD patients were higher than those in early-stage PD patients,” they found.

However, if IGF-1 levels were indicative of disease progression, the neuroprotective hormone was also an indication of whether a patient was likely to experience nonmotor symptoms. “Plasma IGF-1 levels in the PD patients were lower in the anxiety subgroup, depression subgroup, and cognitive dysfunction subgroup than in the subgroups without anxiety,” the authors reported.

In addition, IGF-1 levels were positively correlated with gray matter volume in the insula, caudate, and anterior cingulate. The authors noted that previous research suggests that IGF-1 can help protect against neurotoxicity associated with 3-hydroxyglutaric acid, which they said is believed to cause degeneration of the caudate and putamen nuclei. A study in a mouse model suggested that the inverse was true, too: IGF-1 could increase the volume of the caudate nucleus region.

“All this evidence suggests that IGF-1 can exert neuroprotective effects and its expression can be increased in the caudate nucleus,” the authors wrote.

In conclusion, they said the study’s findings make a strong case that monitoring IGF-1 might be a way to better monitor patients and plan treatment programs for them. They said larger studies will be needed to confirm the findings of this study and better explore the potential mechanisms behind these correlations.

Reference
Shi X, Zheng J, Ma J, et al. Insulin-like growth factor in Parkinson’s disease is related to nonmotor symptoms and the volume of specific brain areas. Neuroscience Letters. Published online June 13, 2022. doi:10.1016/j.neulet.2022.136735

Strength Training Safely Boosts Muscular Dystrophy Outcomes, but Further Study Needed
Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Complement Inhibitors Suggested to Benefit Treatment Outcomes in PNH
A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
COVID-19 Pandemic's Disruption on Cancer Detection in the US
A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.
Read More
Identifying Patients at High Risk of Myeloid Neoplasms After CAR T: Implications for Care, Surveillance
For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Read More
Strength Training Safely Boosts Muscular Dystrophy Outcomes, but Further Study Needed
Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Complement Inhibitors Suggested to Benefit Treatment Outcomes in PNH
A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
COVID-19 Pandemic's Disruption on Cancer Detection in the US
A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.
Read More
Identifying Patients at High Risk of Myeloid Neoplasms After CAR T: Implications for Care, Surveillance
For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Read More
2 Commerce Drive
Cranbury, NJ 08512
609-716-7777

source

About The Author

admin

See author's posts